MedTrace Logo

Safety and Efficacy of MET-3 in Obese Human Subjects

NCT03660748 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2020-08-11

No results posted yet for this study

Summary

A pilot study to explore the metabolic effect and safety of a 3-week course of therapy with MET-3 in obese subjects

Conditions

Interventions

BIOLOGICAL

MET-2

Ingestion of a novel human microbiome preparation

Sponsors & Collaborators

  • Glycemic Index Laboratories, Inc

    collaborator INDUSTRY

  • NuBiyota

    lead OTHER

Principal Investigators

  • Thomas MS Wolever, MD/PhD · GI Labs

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2020-01-22
Completion
2020-01-22

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03660748 on ClinicalTrials.gov